Assessing characteristics and outcomes of patients with Marginal Zone Lymphomas
Retrospective Observational Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
This study looks at the experiences and treatment results of patients with Marginal Zone B Cell Lymphoma to better understand the disease and improve care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, Bologna) |
| Trial ID | NCT06806488 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with Marginal Zone B Cell Lymphoma at a single hospital between December 2012 and December 2018. It aims to retrospectively analyze the clinical characteristics and treatment outcomes of these patients. By compiling and reviewing patient data, the study seeks to provide insights into the disease's progression and management. The findings may help improve understanding and treatment strategies for this specific type of lymphoma.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who were diagnosed and treated for Marginal Zone Lymphoma at the participating hospital during the specified timeframe.
Not a fit: Patients diagnosed with Marginal Zone Lymphoma outside the specified time frame or those treated at other institutions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of Marginal Zone Lymphoma, leading to better treatment approaches for patients.
How similar studies have performed: While this study is observational and retrospective, similar studies have provided valuable insights into lymphoma characteristics and outcomes, suggesting potential for meaningful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018. 2. Age ≥ 18 years at enrolment. 3. Written informed consent (if applicable) Exclusion Criteria: * none
Where this trial is running
Bologna, Bologna
- IRCCS Azienda Ospedaliero - Universitaria di Bologna — Bologna, Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Pier Luigi Zinzani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Pier Luigi Zinzani, MD
- Email: pierluigi.zinzani@unibo.it
- Phone: +39 0512143680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.